Brent Evans

Brent Evans currently serves as the Senior Director of Qualified Treatment Center Account Engagement at bluebird bio, focusing on gene therapy for sickle cell disease, beta thalassemia, and cerebral adrenoleukodystrophy since October 2022. In previous roles, Evans was the Associate Director of US Market Access at Seagen, responsible for strategic payer accounts in the Midwest, and held the Director of Field Access position at Deciphera Pharmaceuticals, overseeing the launch of Qinlock in the oncology marketplace. Evans has extensive experience in oncology access and reimbursement, having worked as a Regional Account Executive at Takeda Oncology and as a Government Payer Manager at Hoffman La Roche. Early career highlights include leading a national group purchasing organization as Executive Vice President and General Manager at RC Medical, and serving as Vice President of Sales and Marketing at Quintex, Inc. Brent Evans holds a Bachelor of Arts in Communications and Marketing from Bowling Green State University.